TY - JOUR
T1 - EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria
AU - Van Der Heijde, Désirée
AU - Van Der Helm-Van Mil, Annette H M
AU - Aletaha, Daniel
AU - Bingham, Clifton O.
AU - Burmester, Gerd R.
AU - Dougados, Maxime
AU - Emery, Paul
AU - Felson, David
AU - Knevel, Rachel
AU - Kvien, Tore K.
AU - Landewé, Robert B M
AU - Lukas, Cédric
AU - McInnes, Iain
AU - Silman, Alan J.
AU - Smolen, Josef S.
AU - Stanislawska-Biernat, Ewa
AU - Zink, Angela
AU - Combe, Bernard
PY - 2013/4
Y1 - 2013/4
N2 - The aim of this report was to propose a definition for erosive disease in the context of inflammatory arthritis in light of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) criteria for use in clinical practice and studies. A EULAR task force was formed including 16 rheumatologists and one rheumatology fellow. The process was both evidence based and consensus based, and included, between March 2010 and April 2012, analyses of data from two cohorts, two face-to-face meetings, one online voting and one teleconference. The Leiden Early Arthritis Cohort and the French ESPOIR cohort were used for the evidence-based part. The outcome measures, which were initiation of methotrexate therapy, or any disease-modifying antirheumatic drug therapy within the first year of disease and arthritis persistency over 5 years, were studied with the aim to give the best definition of erosive disease. A decision was made to select a definition with a high specificity and focus on patients who did not otherwise fulfil the 2010 ACR/EULAR RA criteria (
AB - The aim of this report was to propose a definition for erosive disease in the context of inflammatory arthritis in light of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) criteria for use in clinical practice and studies. A EULAR task force was formed including 16 rheumatologists and one rheumatology fellow. The process was both evidence based and consensus based, and included, between March 2010 and April 2012, analyses of data from two cohorts, two face-to-face meetings, one online voting and one teleconference. The Leiden Early Arthritis Cohort and the French ESPOIR cohort were used for the evidence-based part. The outcome measures, which were initiation of methotrexate therapy, or any disease-modifying antirheumatic drug therapy within the first year of disease and arthritis persistency over 5 years, were studied with the aim to give the best definition of erosive disease. A decision was made to select a definition with a high specificity and focus on patients who did not otherwise fulfil the 2010 ACR/EULAR RA criteria (
U2 - 10.1136/annrheumdis-2012-202779
DO - 10.1136/annrheumdis-2012-202779
M3 - Article
C2 - 23378540
SN - 0003-4967
VL - 72
SP - 479
EP - 481
JO - Annals of the rheumatic diseases
JF - Annals of the rheumatic diseases
IS - 4
ER -